Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 6, 2003. The report details a specific corporate action regarding share re-purchases executed in accordance with shareholder authority granted at the Annual General Meeting on May 20, 2002.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share re-purchase transaction:
- Shares Purchased: 930,000 Ordinary 25 pence shares.
- Transaction Date: March 5, 2003.
- Price per Share: 1,068.87 pence.
- Purpose: Purchase for cancellation.
Material Changes
The filing does not disclose material changes in financial performance or operations compared to prior periods. The primary change reported is the reduction of the company's share capital through the cancellation of 930,000 shares.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, risk factors, or contingencies. It is a routine disclosure of a completed share buyback transaction.
Key Facts for Investor Verification
- Verify the total number of shares authorized for re-purchase under the May 20, 2002 shareholder resolution to determine remaining capacity.
- Confirm the total cost of the transaction (930,000 shares x 1,068.87 pence) against the company's cash reserves in subsequent filings.
- Check subsequent filings to see if this was part of a larger, ongoing re-purchase program.